

PARTICIPACIÓN DE GEICAM EN EL CONGRESO DE LA ESMO



2023 European Society of Medical Oncology (ESMO) Annual Congress

October 20-24, 2023, Madrid

1 comunicación oral y comunicación (X póster)

Estudios de promotor GEICAM

TIPO	TÍTULO	AUTORES	
Póster	Body Mass Index as a predictive factor for efficacy of taxane-based chemotherapy in early breast cancer patients	García-Saenz JA , Spera G, Pollán M, Bermejo B, Ruiz-Borrego M, Chan A, Martín M, Guerrero-Zotano A, Calvo L, Rodríguez-Lescure A, Arcusa A, Chap L, Crown J, Bee V, Casas M, Polonio O, Slamon D	Presentation Number 251P Onsite Poster display date Saturday, 21 October 2023

PARTICIPACIÓN DE GEICAM EN EL CONGRESO DE LA ESMO

Estudios con participación de GEICAM

TIPO	TÍTULO	REFERENCIA
Comunicación oral	Invasive disease-free survival (iDFS) across key subgroups from the Phase III NATALEE study of ribociclib (RIB) + a nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2- early breast cancer (EBC)	Presentation Number: LBA23 Speakers: Aditya Bardia (Boston, United States of America) Lecture Time: 10:50 - 10:55 Session Name: Mini oral session - Breast cancer, early stage (ID 267) Room: Bilbao Auditorium - NCC Date: Mon, 23.10.2023 Time: 10:15 - 11:45
Comunicación oral	Impact of body mass index and its change on survival outcomes in patients with early breast cancer: a pooled analysis of individual-level data from BCIRG-001 and BCIRG-005 trials	Presentation Number: 239MO Speakers: Haizhu Chen (Beijing, China) Lecture Time: 10:25 - 10:30 Session Name: Mini oral session - Breast cancer, early stage (ID 267) Room: Bilbao Auditorium - NCC Date: Mon, 23.10.2023 Time: 10:15 - 11:45
Póster	Cost-effectiveness of first line (1L) ribociclib use vs palbociclib in the treatment of postmenopausal women with HR+/HER2- advanced breast cancer (ABC): analysis based on final overall survival (OS) results of MONALEESA-2 (ML-2) and PALOMA-2 (PAL-2)	Presentation Number: 416P Speakers: Sandeep Sehdev (Ottawa, Canada) Onsite Poster display date: Saturday, 21 October 2023
Póster	Phase Ib safety and efficacy of nadunolimab/gemcitabine/carboplatin (NadGC) in metastatic triple negative breast cancer (mTNBC)	Presentation Number: 406P Speakers: Sara Lopez-Tarruella Cobo (Madrid, Spain) Onsite Poster display date: Saturday, 21 October 2023

PARTICIPACIÓN DE GEICAM EN EL CONGRESO DE LA ESMO

TIPO	TÍTULO	REFERENCIA
Póster (TiP)	Phase III study to evaluate the efficacy and safety of GLSI-100 (GP2 + GM-CSF) in breast cancer patients with residual disease or high-risk PCR after both neo-adjuvant and postoperative adjuvant anti-HER2 therapy, Flamingo-01	Presentation Number: 353TiP Speakers: Snehal Patel (Sugar Land, United States of America) Onsite Poster display date: Saturday, 21 October 2023
Póster (TiP)	A phase 3 randomised open-label study of extended adjuvant therapy with camizestrant vs standard endocrine therapy (ET) in patients with ER+/HER2- early breast cancer (BC) and an intermediate or high risk of recurrence (CAMBRIA-1)	Presentation Number: 354TiP Speakers: Erika P. Hamilton (Nashville, United States of America) Onsite Poster display date: Saturday, 21 October 2023
Póster (TiP)	EORTC BCG 1984 - NOBLE - Neoadjuvant Olaparib and Durvalumab for patients with BRCA-associated TripLE Negative Breast Cancer	Presentation Number: 351TiP Speakers: Emanuel Buhner (Brussels, Belgium) Onsite Poster display date: Saturday, 21 October 2023